ElevateBio is a technology-driven genetic medicines company, accelerating access to cutting-edge technologies, end-to-end manufacturing capabilities, and expertise to advance the cell and gene therapy industry. The company's integrated ecosystem of technologies and capabilities enables the discovery, development, manufacturing, and commercialization of a broad spectrum of cell and gene therapies and regenerative medicines.

ElevateBio

Life Edit Therapeutics

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, ElevateBio BaseCamp is a purpose-built, technology-enabled manufacturing platform offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities for viral vectors, RNA, and cell therapy production. Through BaseCamp, its expanding footprint, and its next-generation enabling technologies, ElevateBio is rapidly growing its collaborations with industry partners while also selectively developing its own portfolio of cellular and genetic medicines. 

ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

AlloVir

Samsara BioCapital

Surveyor Capital

Vertex Ventures

Invus

ITOCHU Corporation

Redmile Group

EDBI

Emerson Collective

F2 Ventures

Fidelity Management and Research Company

Woodline Partners

Matrix Capital Management

Novo Nordisk

Fidelity

Exciting news!  Life Edit Therapeutics Chief Scientific Officer, Tedd Elich, was recently highlighted in BioPharm International in the feature, "Milestone Approval to Steady Stream, Gene Editing Revs Up." Gain valuable insights into the future of gene editing, technology advancements, and more. Access the full article in the comments below.

Our Life Edit gene editing business offers diverse tools for unlimited gene editing. This platform boasts the ability to make "any edit anywhere" - from small deletions and insertions to rewriting the DNA sequence – and delivers versatility and flexibility. 

Learn more about partnering with us at https://lnkd.in/gMf9yFkv

#ElevateBio #InnovateAtElevate #GeneticMedicine

No matter where you are with your development journey, our LentiPeak™ platform can help you reach your next milestone faster.

Our proprietary lentiviral vector (LVV) platform is suspension-based and scalable to meet your needs, offering streamlined tech transfers, control strategies for risk mitigation and proven performance with CAR and TCR constructs at multiple production scales.

Take the first step towards elevating our future together: https://lnkd.in/ed8fRD-F.

#GeneManufacturing #ElevateBio

Frank Bugg, our Global Head of BaseCamp Operations will discuss BaseCamp's capabilities in supporting partnerships across research, discovery, analytical development, and more as part of the Outsourced Pharma Capacity Update series on February 15 at 10 am EST. 

Register at https://lnkd.in/eEMjUqyS. 

#ElevateBio #Biotech 

We guide our partners through their journey from concept to commercialization, or at any stage in between. BaseCamp, our cGMP manufacturing facility, is equipped for the full product lifecycle; we have expertise in developing and scaling processes for cell therapies and viral vectors, and we offer analytical and enabling services, too. 
Our proprietary lentiviral vector platform–LentiPeak™–can be fully customized to fit partners’ needs. 

Learn more about the benefits of a strategic relationship with ElevateBio: https://lnkd.in/evp85Xpk.

#BaseCamp #CellTherapy #GeneTherapy


BIO:ELEVATE

ElevateBio